Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: A comparison

Statistics in Medicine

Volumn 25, Issue 6, 2006, Pages 933-941

  Shih, Weichung Joe ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FEASIBILITY STUDY; MATHEMATICAL COMPUTING; NORMAL DISTRIBUTION; NULL HYPOTHESIS; PROCESS OPTIMIZATION; PROPORTIONAL HAZARDS MODEL; SAMPLE SIZE; SEQUENTIAL ANALYSIS;

CLINICAL TRIALS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; RESEARCH DESIGN; SAMPLE SIZE;

EID: 33644773395     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2252     Document Type: Article

References (28)

1. Flexible trials designs: rationale, approaches and controversies (speakers: D. Berry, G. Lan, and S. Ellenberg), ASA Biopharmaceutical Section 2004 FDA/Industry Statistics Workshop, Washington, DC, 21-23 September, 2004.
2. To adaptive or not to adaptive? That's the question (speakers: Q. Liu and C. Jennison), Conference on Adaptive Designs for Clinical Development. IBC Life Sciences, Boston, MA, 24-25 January, 2005.
3. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. Controlled Clinical Trials 1993; 14:183-197.
4. Shih WJ. Sample size reestimation in clinical trials. In Biopharmaceutical Sequential Statistical Applications, Karl Peace (ed.), chapter 18. New York: Marcel Dekker, 1992; 285-301.
5. Gould AL, Shih WJ. Sample size reestimation without unblinding for normally distributed outcomes with unknown variance. Communications in Statistics (A) - Theory and Methods 1992; 21(10):2833-2853.
6. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Statistics in Medicine 1990; 9:65-72.
7. Zucker D, Wittes J, Schabenberger O, Brittain E. Internal pilot studies II: comparison of various procedures. Statistics in Medicine 1999; 18:3493-3509.
8. Young F, Nightingale F, Temple R. The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction. Journal of the American Medical Association 1988; 259:3158-3160.
9. Henneken CH, Buring JE. Methodologic considerations in the design and conduct of randomized trials: The U.S. Physicians' Health Study. Controlled Clinical Trials 1989; 10:142S-150S.
10. Bigger Jr JT, Parides MK, Rolinitzky LM, Meier P, Levin B, Egan DA. Changes in sample size and length of follow-up to maintain power in the Coronary Artery Bypass Graft (CABG) Patch Trial. Controlled Clinical Trials 1998; 19:1-14.
11. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70:659-663.
12. Bauer P, Kohne K. Evaluations of experiments with adaptive interim analyses. Biometrics 1994; 50:1029-1041.
13. Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55:853-857.
14. Shen Y, Cai J. Sample size reestimation in clinical trials with censored survival data. Journal of the American Statistical Association 2003; 98:418-426.
15. Tsiatis AA, Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90:367-378.
16. Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect size under consideration. Statistics in Medicine, ..., 2005.
17. Li G, Shih WJ, Xie T, Lu J. A sample size adjustment procedure for clinical trials based on conditional power. Biostatistics 2002; 3:277-287.
18. Li G, Shih WJ, Wang Y. Two-stage adaptive design for clinical trials with survival data. To appear in Journal of Biopharmaceutical Statistics 2005; 15:1-12.
19. Shih WJ. Adaptive designs for flexibility not midcourse change. ICSA Bulletin 2003; 41-42.
20. Wang SJ, Hung HMJ, Tsong Y, Cui L. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Statistics in Medicine 2001; 20:1903-1912.
21. Shih WJ, Quan H, Li G. Two-stage adaptive strategy for superiority and non-inferiority hypotheses in active controlled clinical trials. Statistics in Medicine 2004; 23:2781-2798.
22. Shih WJ, Ouyang P, Quan H, Lin Y, Michiels B, Bijnens L. Controlling type-I error rate for fast track drug development programs. Statistics in Medicine 2003; 22:665-675.
23. Lan KKG, Soo Y, Shun Z. Select the winner in drug development. FDA-Industry Workshop, Bethesda, Maryland, 18 September, 2003.
24. Proschan M, Hunsbarger S. Designed extension of studies based on conditional power. Biometrics 1995; 51:1315-1324.
25. Elashoff JD, Reedy TJ. Two-stage clinical trials stopping rules. Biometrics 1984; 40:791-795.
26. Chi GYH, Liu Q. The attractiveness of the concept of a prospectively designed two-stage clinical trial. Journal of Biopharmaceutical Statistics 1999; 9:537-547.
27. Liu Q, Chi GYH. On sample size and inference for two-stage adaptive designs. Biometrics 2001; 57:172-177.
28. Lin Y, Shih WJ. An adaptive two-stage design for phase II clinical trials. Biometrics 2004; 60:482-490.